与塞马格卢提德相关的视力障碍报告增加:对FDA不良事件数据的分析
Marine Massy1,2,3, Stefanie Marti1, Helly Hammer1
1Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Rosenbühlgasse 25, Bern, CH-3010, Switzerland.
BMC medicine
|April 6, 2025
概括
与其他糖尿病和减肥药物相比,塞马格卢提德的使用可能与视力受损的风险更高有关. 需要进一步的研究来了解这种潜在风险的临床影响.
科学领域:
- 药物监督 药物监督 药物监督
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
背景情况:
- 作为一种类似葡萄糖类-1 (GLP-1) 受体激动剂的塞马格卢提德,通常用于2型糖尿病和肥胖症.
- 最近,人们对塞马格卢提德的眼睛安全性概况产生了担忧.
- 这项研究调查了塞马格卢提德与视力障碍之间的关联.
研究的目的:
- 分析塞马格卢提德使用与视力障碍之间的潜在关联.
- 为了比较与其他抗糖尿病药物和减肥药物相比,塞马格卢提德的视力障碍报告.
主要方法:
- 利用了来自FDA不良事件报告系统 (FAERS) 的数据.
- 进行了与塞马格卢提德与其他药物相关的视力障碍报告的比较分析.
- 计算报告赔率比率 (rOR) 来评估关联的强度.
主要成果:
- 与GLP-1受体激动剂,DPP-4抑制剂,SGLT2抑制剂和甲胺相比,塞马格卢提德显示出明显更高的视力损伤概率比率.
- 与减肥药物fentermine和orlistat的比较也显示了semaglutide的报告率更高.
- 托皮拉是唯一一种比塞马格卢提德报告视力障碍的几率比率较低的药物.
结论:
- 研究结果表明,相对于其他常用的药物相比,塞马格卢提德使用可能会增加与视力障碍相关的视力损伤风险.
- 推进行警的营销后监测,以监测眼睛的安全性.
- 需要进行进一步的研究,以评估赛马格卢提德视力损伤的临床意义和绝对风险.
相关概念视频
01:25Glaucoma: Overview
482
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
482
01:22Photoreceptors and Visual Pathways
5.5K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
5.5K
01:28Angle Closure Glaucoma: Treatment
403
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
403
01:27Open Angle Glaucoma: Treatment
368
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
368
01:23Dipeptidyl Peptidase 4 Inhibitors
142
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
142
01:27Glucose Transporters
22.3K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.3K